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Abstract
Although the development of hematopoietic stem cells (HSC) has been studied in great detail, their heterogeneity and rela-
tionships to different cell lineages remain incompletely understood. Moreover, the role of Vascular Adhesion Protein-1 in 
bone marrow hematopoiesis has remained unknown. Here we show that VAP-1, an adhesin and a primary amine oxidase 
producing hydrogen peroxide, is expressed on a subset of human HSC and bone marrow vasculature forming a hematogenic 
niche. Bulk and single-cell RNAseq analyses reveal that VAP-1+ HSC represent a transcriptionally unique small subset of 
differentiated and proliferating HSC, while VAP-1− HSC are the most primitive HSC. VAP-1 generated hydrogen peroxide 
acts via the p53 signaling pathway to regulate HSC proliferation. HSC expansion and differentiation into colony-forming 
units are enhanced by inhibition of VAP-1. Contribution of VAP-1 to HSC proliferation was confirmed with mice deficient 
of VAP-1, mice expressing mutated VAP-1 and using an enzyme inhibitor. In conclusion, VAP-1 expression allows the char-
acterization and prospective isolation of a new subset of human HSC. Since VAP-1 serves as a check point-like inhibitor in 
HSC differentiation, the use of VAP-1 inhibitors enables the expansion of HSC.
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Introduction
Hematopoietic stem cells give rise to all hematopoietic 
cells through self-renewal and differentiation [1, 2]. Post-
natally HSC reside in the bone marrow (BM) niche [3], 
but for therapeutic purposes they are also collected from 
the cord or adult blood [4, 5]. Traditionally HSC have 
been thought to give successively rise to multipotent and 
unipotent progenitors, which then produce different line-
ages of hematopoietic cells [6, 7]. High-resolution molecular 
analyses, trajectory analyses and cell-fate mapping studies 
have recently challenged this concept, and suggest the pres-
ence of a previously unknown heterogeneity among human 
hematopoietic progenitors [8–10]. The HSC and their early 
progenitors  (Lin−CD34+CD38− cells) are undifferentiated 
cells [11] and they gradually mature to more differentiated 
progeny cells  (Lin−CD34+CD38+), which have heterogenic 
transcriptional signatures [12] and are lineage-restricted 
progenitors containing all major branches of bone marrow 
hematopoiesis [13]. However, it is evident that not all cell 
differentiation properties are reflected in the transcriptome, 
and thus alternative levels, possibly epigenetic, proteomic or 
microenvironmental, controlling cell fate do exist [14–17].
Vascular adhesion protein-1 (VAP-1) is a transmembrane 
protein also known as amine oxidase copper-containing 3 
and semicarbazide-sensitive amine oxidase (SSAO) [18]. 
The extracellular amine oxidase activity of VAP-1 catalyzes 
oxidative deamination of amines into their corresponding 
aldehydes and produce ammonia and hydrogen peroxide, 
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one of the reactive oxygen species (ROS) [19]. Interestingly, 
ROS regulate the function of HSC [20, 21]. In particular, 
high levels of ROS restrict the life-span of HSC [22, 23].
In this work, we describe the characteristics of a unique 
human VAP-1+ HSC subpopulation within undifferentiated 
HSC and its role in controlling HSC proliferation in vitro 
and in vivo. These data offer new molecular insights into 
the heterogeneity of HSC, define VAP-1 produced hydrogen 
peroxide as a check point-like inhibitor for HSC proliferation 
and may provide new ways for HSC expansion for clinical 
use in the future. Moreover, by using VAP-1 knockout mice 
and VAP-1 inhibitor treatments we demonstrate that VAP-1 
in BM vasculature supports HSC expansion.
Materials and methods
Mice and human samples
Fresh human BM cells from 11 donors from AllCells, Lonza 
and Helsinki University Hospital and cord blood (CB) cells 
from Turku University Hospital were obtained. Anonymous 
human samples were obtained with the permission of the 
Ethical Committees of Turku and Helsinki University Hos-
pitals. NBSGW mice (NOD.Cg-KitW-41 J Tyr + Prkdcscid 
Il2rgtm1Wjl/ThomJ) were from the Jackson Laboratory. 
Full VAP-1 knockout (KO) mice [24], VAP-1 knock-in (KI) 
mice, which express enzymatically inactive VAP-1 [25] and 
their wild type (WT) controls (C57BL/6 J WT mice) were 
littermates of heterozygous VAP-1-KO animals from our 
own colonies. All experimental mice were sex- and age-
matched. In bone marrow transplantation studies (utilizing 
LJP-1586 treatment) female mice were used because of their 
better acceptance of transplants [26]. All other studies were 
performed using both male and female mice. The mice were 
handled in accordance to the institutional animal care policy 
of the University of Turku and following national and EU 
guidelines. All animal experiments were approved by the 
Finnish Animal Ethics Committee.
Flow cytometry and cell sorting
Detailed information about the antibodies used in this study 
is provided in the Supplemental Table 1.
Fresh human BM and CB cells were first incubated with 
5% human serum and human IgG (100 µg/ml) for 15 min 
at room temperature (RT) in order to reduce staining back-
ground for the fluorescein isothiocyanate (FITC) labeled 
anti-VAP-1 antibodies. The cells were then stained with the 
monoclonal antibodies 1B2, TK8-14, and/or JG-2, which 
recognize different epitopes of human VAP-1, or with 
commercial control mouse IgG and IgM against chicken 
bursal epithelium as isotype controls. All antibodies were 
conjugated to FITC using standard procedures. The follow-
ing additional HSC marker antibodies were also used: APC-
conjugated mouse anti-CD34, PE-Cy7-conjugated mouse 
anti-CD34, PE-conjugated mouse anti-CD34, PE-conjugated 
rat anti-CD49f, PE-Cy7-conjugated mouse anti-CD45RA, 
PerCP-Cy5.5-conjugated mouse anti-CD45RA, BV421-
conjugated mouse anti-CD38, APC-conjugated mouse 
anti-CD38, BV510-conjugated rat anti-CD49f, BV605-con-
jugated mouse anti-CD90, APC-conjugated mouse anti-Lin-
eage cocktail, and APC-Cy7-conjugated mouse anti-CD90. 
Cells were incubated with antibodies for 15 min at 4 °C. 
Live cells were identified based on forward and side scatter 
plots. Cells were sorted on a FACSAria IIu instrument (BD 
Biosciences) or analyzed with a LSR Fortessa instrument 
(BD Biosciences) using FlowJo software (Tree Star).
Mouse BM cells were collected using a BM Harvesting 
& Hematopoietic Stem Cell Isolation Kit (Millipore). Cells 
were stained with a rabbit anti-VAP-1 polyclonal antibody, 
a rat anti-VAP-1 monoclonal antibody 7–106 (IgG2b), nega-
tive controls (rabbit IgG or rat IgG2b), followed by appropri-
ate FITC-conjugated goat anti-rabbit IgG and FITC-conju-
gated anti-rat IgG secondary antibodies. APC-conjugated 
anti-mouse Lineage cocktail, a PE-Cy7-conjugated rat anti-
CD127 antibody, a PE-CF594-conjugated rat anti-CD135 
antibody, a FITC-conjugated rat anti-CD41 antibody, a 
Brilliant Violet 510-conjugated rat anti-c-Kit antibody, a 
PE-Cy7-conjugated rat anti-CD48 antibody, a PE-conju-
gated rat anti-CD150 antibody, and a PE-conjugated rat anti-
Sca-1 antibody were incubated for 30 min on ice. Samples 
were evaluated on an LSR Fortessa instrument, and data 
were analyzed using FlowJo software (Tree Star).
Immunocytochemistry
FACS sorted  CD34+ CB cells were spinned on glass slides 
by centrifugation at 1000 rpm for 5 min, and fixed with cold 
acetone for 5 min. For immunofluorescence assays, cyto-
spined cells were blocked with 5% human AB serum. Cells 
were stained with either combination of FITC conjugated 
rabbit anti-VAP-1 polyclonal antibody, TK8-14 and JG-2 
monoclonal antibodies; or combination of FITC conjugated 
pre-bleed serum from the same rabbit, and isotype-control 
mouse IgG2a. Finally, the cells were mounted using Prolong 
Gold anti-fade reagent with 4′,6-diamidino-2-phenylindole 
(DAPI; Molecular Probes). Images were acquired using an 
Olympus BX60 microscope. Background subtraction and 
adjustments of brightness and contrast were performed using 
ImageJ software.
Frozen murine tissue sections. (5 μm thick) were stained 
with a rabbit anti-VAP-1 primary antibody (made against 
recombinant human VAP-1 but also recognizing mouse 
VAP-1 [27]) followed by an Alexa Fluor 546-conjugated 
goat anti-rabbit IgG (H + L) secondary antibody (Invitrogen). 
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The following directly conjugated antibodies were also used: 
eFluor 450-conjugated rat anti-mouse CD150 (eBioscience), 
APC-conjugated rat anti-mouse Lineage antibody cocktail 
(BD Biosciences), Alexa Fluor 488-conjugated rat anti-
mouse CD31 (Biolegend). The sections were mounted using 
ProlongGold anti-fade reagent (Molecular Probes). Images 
were acquired using a LSM780 confocal microscope (Carl 
Zeiss) or an Olympus BX60 microscope and analyzed using 
Zen 2010 (Carl Zeiss) or ImageJ software.
For whole-mount staining a mouse femur was fragmented 
into small pieces, which were incubated with 5% normal 
mouse serum for 10 min at  RT with gentle rotation. There-
after, BM pieces were incubated with a rabbit anti-VAP-1 
antibody (1:500) overnight at 4 °C without rotation, washed 
with PBS for 30 min at RT, and then incubated with Alexa 
Fluor 546-conjugated anti-rabbit IgG for 15 min at RT with 
gentle rotation. After washing with PBS for 30 min at RT 
with gentle rotation, BM pieces were incubated with APC-
conjugated anti-CD31 and Alexa Fluor 488- conjugated 
anti-PV-1 (MECA-32) for 30 min at RT. Finally, BM pieces 
were washed with PBS for 10 min at RT with gentle rotation. 
Images were acquired using a 3i Marianas spinning disk 
confocal microscope (Intelligent Imaging Innovations, Inc) 
equipped with a Plan-apochromat 20 × /0.8 objective (Carl 
Zeiss), a Yokogawa CSU-W1 scanner, and a Hamamatsu 
sCMOS Orca Flash 4 (2048 × 2048 pixels) camera. Total of 
57 optical sections with a slice thickness of 0.63 μm were 
acquired. Images were analyzed using SlideBook 6 software 
(Intelligent Imaging Innovations, Inc.).
RNAseq analysis
Fresh human BM (n = 4, Lonza) were first incubated with 
5% human serum and human IgG (100 µg/ml) for 15 min at 
RT. Then the BM cells were stained with the FITC conju-
gated monoclonal antibodies 1B2, TK8-14, and/or JG-2. The 
following additional HSC marker antibodies were also used: 
PE-Cy7-conjugated mouse anti-CD34, PE-conjugated rat 
anti-CD49f, PerCP-Cy5.5-conjugated mouse anti-CD45RA, 
APC-conjugated mouse anti-CD38, BV421-conjugated rat 
anti-CD90, APC-conjugated mouse anti-Lineage cocktail. 
Cells were incubated with antibodies for 15 min at 4 °C. 
Live cells were identified based on forward and side scatter 
plots. Cells were sorted on a Sony SH800 cell sorter with 
class A2 Level II biosafety cabinet using 130 µm microflu-
idic sorting chips.
Total of 117–150 VAP-1+ and VAP-1− HSC from each 
individual were used for sequencing. Sequencing libraries 
were generated using: SMART-Seq v4 Ultra Low Input 
RNA Kit, Takara (012,516), Illumina Nextera XT DNA 
Library Preparation, Illumina (15,031,942), SMART-seq 
v4 Ultra Low Input RNA Kit (Takara), Nextera XT DNA 
Library Preparation Kit (Illumina), Nextera XT Index Kit V2 
(Illumina). The libraries were sequenced with HiSeq 3000 
(Illumina). After library preparation, quality was ensured 
using Agilent Bioanalyzer 2100. Sequencing was performed 
at the Finnish Functional Genomics Centre (FFGC) using 
Hiseq3000 Next-Generation Sequencing platforms (Illu-
mina). 260–320 M reads/lane data was generated Hiseq3000 
run. Raw data were delivered as a fastq format (FFGC). The 
RNA-seq data have been deposited to the Gene Expression 
Omnibus with SRA accession number PRJNA594799.
RNA-sequencing data analyses followed that of Kumar 
et al. [28] and included pre-processing of read data using 
Trimmomatic [29], gap-aware alignment of the read data 
to the human reference genome (Ensembl GRCh38) with 
the guidance of the EnsEMBL reference gene models 
(EnsEMBL v82) using the 2-pass per-sample mapping 
approach in STAR [30] and read summarization against 
EnsEMBL v82 gene and exon features using Rsubread [31]. 
Default parameters were used with the exception that reads 
were allowed to be assigned to more than one matched meta-
feature in feature counting. Quality statistics was generated 
using FastQC and RNA-SeQC [32] and manually inspected.
Low expressed genes were removed from the dataset as a 
preliminary step. A gene was considered not expressed if the 
counts per million (CPM), standardized by the correspond-
ing library size, were less than one in at least half of the sam-
ples in both VAP-1+ and VAP-1−groups. After gene filter-
ing the dataset contained a total of 14,943 expressed genes, 
down from 60,619 total genes. Expression estimates were 
normalized with the Trimmed Mean of M-values (TMM) 
method [33] in all subsequent analyses.
GSE and pathway analyses
Gene set enrichment analysis (GSEA, pre-ranked) was per-
formed using the tool from the Broad Institute [34]. Pathway 
analyses were performed using STITCH database (http:// 
stitch. embl. de/). To construct the network, interactions with 
a minimum confidence score 0.40 were considered signifi-
cant and extracted for constructing the PPI network.
Quantitative PCR
To detect TPX2, CDCA8, PCNA, MLLT3 and TYMS 
FACS sorted human BM VAP-1+ and VAP-1− HSC 
 (Lin−CD34+CD38−  CD45RA−  CD90+) were used. Super-
Script IV CellsDirect cDNA Synthesis Kit (ThermoFisher 
Scientific) was applied for direct cDNA synthesis using 
sorted cell lysis protocol. One cell equivalent cDNA was 
used for RT-PCR using TaqMan Fast Advanced Master Mix 
(ThermoFisher Scientific). The following TaqMan Assays 
were used: Hs00187842_m1 (B2M), Hs00201616_m1 
(TPX2), Hs00983655_m1 (CDCA8), Hs00427214_g1 
(PCNA), Hs00426586_m1(TYMS) all from ThermoFisher 
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Scientific. cDNA was analyzed by real-time qPCR (7900HT 
Fast Real-Time PCR System, Applied Biosystems). The 
results were analyzed in Applied Biosystems qPCR analysis 
modules. The expression values were normalized using β2 
microglobulin expression as endogenous controls.
scRNAseq analysis
Fresh human BM cells (Lonza) from one donor were first 
incubated with 5% human serum for 15 min at RT. Then the 
BM cells were stained with the FITC conjugated monoclo-
nal antibodies 1B2, TK8-14, and/or JG-2 and PE-Cy7-con-
jugated mouse anti-CD34 as well as with APC-conjugated 
mouse anti-Lineage cocktail. Live cells were identified 
based on forward and side scatter plots. Cells were sorted 
on a Sony SH800 cell sorter with class A2 Level II biosafety 
cabinet using 130 µm microfluidic sorting chips. Total of 
four samples, two technical replicates of each (VAP-1+ and 
VAP-1− populations) were immediately loaded into the 
10XGenomics Chromium controller for gel-bead-in-emul-
sion formation (Turku Bioscience Single-cell Omics core 
facility and Finnish Functional Genomics Centre supported 
by University of Turku, Åbo Akademi University and Bio-
center Finland).
Single Cell 3ʹ Reagent Kits v3.1 (Dual Index) were used 
according to the manufacturer’s protocol (CG000315). In 
brief, for each sample, 30–40 μl of single-cell suspension at 
concentration of 400 cells/μl was loaded on a separate lane 
of the Next GEM Chip G, targeting at recovery of approxi-
mately 10,000 cells per sample. During the run, single-cell 
barcoded cDNA is generated in nanodroplet partitions. The 
droplets are subsequently reversed, and the remaining steps 
are performed in bulk. The barcoded cDNA was amplified 
using 12 PCR cycles using a Veriti thermal cycler (Ther-
moFisher). The amplified cDNA was then subjected to frag-
mentation, end repair and A-tailing, adapter ligation, and 
sample index PCR (13 cycles). The gene expression libraries 
were sequenced using an Illumina NovaSeq 6000 and an 
S1 flow cell with the following read length configuration: 
Read1 = 28, i7 = 10, i5 = 10, Read2 = 90. The raw data was 
processed using Cell Ranger 5.0.1. with GRCh38 as the ref-
erence genome.
Bioinformatics of single‑cell RNA sequencing
Previously sequenced HSC data (GEO accession code 
GSM3305359) were downloaded from NCBI [10]. Seurat 
(https:// satij alab. org/ seurat/) (version 3.1) [35] implemented 
in R (version 3.6) under anaconda environment was applied 
to reduce the dimension of HSC-derived datasets. Data gen-
erated in this manuscript were analyzed in R version 4.0.5 
using Seurat suite version 4.0.1 under anaconda environ-
ment. Cells were excluded, if the number of genes detected 
was below 100 or the percentage of mitochondrial genes 
above 20% followed by log-normalization using “Normal-
izeData” on a scale factor as 10,000. All variable genes were 
detected by “FindVariableFeatures” and genes passing the 
“vst” filter were included in the following analysis. Linear 
transformation was done using “ScaleData” function. Prin-
cipal component analysis (PCA) was performed using “Run-
PCA” function and reported by “JackStraw” procedure and 
only significant PCs were selected using the elbow method 
to perform dimension reduction and clustering. Cells were 
projected in 2D space using non-linear dimensional reduc-
tion techniques (UMAP) with default parameters. For dif-
ferential expression analysis to find DEGs among different 
clusters, “FindMarkers” function with default parameters 
was applied. Marker genes of different clusters were selected 
using Wilcoxon Rank Sum test. Signature gene expression 
was calculated as percentage of sum counts of selected genes 
vs all expressed genes. The percentage ratio was added as a 
feature value to each cell and multiplied by 100. Sub-clus-
tering analysis was performed according to a recommended 
procedure by Seurat. Trajectory was constructed with the 
Monocle 2 package (v2.10.1) [36] according to the docu-
mentation (http:// colet rapne ll- lab. github. io/ monoc le- relea se) 
and kernel density estimation was done using Nebulosa R 
package (https:// github. com/ powel lgeno micsl ab/ Nebul osa).
Meta and Gene Ontology (GO) analyses
GO biological process and pathway enrichment analyses 
were performed using Metascape (https:// metas cape. org/) 
[37]. From bulk RNAseq, 687 VAP-1+ and 378 VAP-
1− genes (fold change > 1, p-value < 0.05); and from scR-
NAseq 371 VAP-1+ and 50 VAP-1− genes (according to 
Seurat recommended way) were applied for analysis. G1/S 
and G2/M cell cycle genes and aorta-gonad-mesonephros 
containing HSPC1, HSPC2 and HSPC3 gene signatures 
were collected from previously defined gene sets [38, 39].
Isolation of  CD34+ cells and sorting of VAP‑1+and 
VAP‑1−  HSC from human umbilical CB
CD34+ cells from human umbilical CB were isolated via a 
two-step procedure using Ficoll-Plaque gradient centrifuga-
tion (Amersham Pharmacia Biotech, Uppsala, Sweden) and 
EasySep Human Cord Blood CD34 Positive Selection Kit II 
(STEMCELL Technologies). For batch and single cell sort-
ing of VAP-1+ and VAP-1− cells from CB we used a Sony 
SH800 cell sorter. This sorter applies low shear stress on 
cells allowing better survival during cell culture.  CD34+ cells 
separated by magnetic beads (Stem Cell Technologies) were 
sorted into VAP-1+ and VAP-1− HSC using the following 
markers:  Lineage−CD34+CD38−CD90+CD45RA−CD49f+. 
The sorted cells were then cultured as single cells in 96 
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well plates with Methocult GF + H4435 medium (Stem 
Cell Technologies). Single cells were cultured for 14 days, 
washed and replated as single colonies in 24 well plates for 
another 12 -14 days. Colonies were evaluated for CFUs by 
light microscopy.
Liquid cultures, colony‑forming unit (CFU) 
and long‑term culture‑initiating cell (LTC‑IC) assays
For human umbilical CB cells, an antibody-based EasySep 
kit was used to enrich  CD34+ CB cells, which were sub-
sequently stained with anti-CD38 and anti-CD34 antibod-
ies.  CD38−CD34+ cells were sorted using a FACSAria IIu 
instrument (BD Biosciences) and then cultured in StemSpan 
SFEM medium II (STEMCELL Technologies) containing 
human stem cell factor (100 ng/ml), FMS-like tyrosine 
kinase 3 ligand (100 ng/ml), and thrombopoietin (50 ng/
ml) (all from Peprotech). Cells were seeded at a density of 
1 ×  103 per ml. LJP-1586 was added immediately after plat-
ing when indicated. Cultures were maintained for 21 days, 
and half of the medium was replaced by new medium con-
taining the same cytokines and LJP-1586 on days 5, 8, 12, 
15, and 18.
Five hundred cryopreserved and thawed human BM 
 CD34+ cells (AllCells) were cultured in complete methyl-
cellulose-based medium (H4436, STEMCELL Technolo-
gies) with or without LJP-1586. After 12 days, cells were 
resuspended, re-plated the second time after increasing the 
volume of the culture by tenfold, resuspended again, and re-
plated the third time after increasing the volume of the cul-
ture by fivefold. The total number of colonies was counted 
at 14 days after plating.
The mouse colony-forming unit (CFU) assay was per-
formed using methylcellulose-based MethoCult GF M3434 
medium (STEMCELL Technologies). BM and peripheral 
blood cells were seeded in triplicate, and colonies were 
scored after 12 days. The mouse long-term culture-initi-
ating cell (LTC-IC) assay was performed according to the 
manufacturer’s instructions.. Briefly, stromal feeder layers 
were prepared using total BM cells isolated from the femurs 
and tibias of WT and VAP-1-KO mice. BM was cultured 
in long-term culture medium (MyeloCult M5300 contain-
ing  10−6 M hydrocortisone; STEMCELL Technologies) for 
2 weeks, during which time half the medium was replaced 
every week. Feeder layers at 80% confluency were irradi-
ated with 1500 cGy using an X-ray source. Resuspended 
and unprocessed BM cells from WT and VAP-1-KO mice 
were cultured in long-term culture medium on the irradiated 
feeder layer. Cultures were maintained for 4 weeks, during 
which time half the medium was replaced every week. Non-
adherent cells were harvested and grown in methylcellulose-
based medium (MethoCult GF M3434, STEMCELL Tech-
nologies) for an additional 12 days. Plates were scored as 
positive or negative to yield the LTI-IC frequency respond-
ing or nonresponding.
Measurements of ROS production
Human  CD34+ BM cells were liquid cultured for nine days 
in StemSpan SFEM medium II (STEMCELL Technologies) 
containing human stem cell factor (100 ng/ml), FMS-like 
tyrosine kinase 3 ligand (100 ng/ml), and thrombopoietin 
(50 ng/ml) (all from Peprotech) with or without LJP-1586. 
After nine days, the cells were stained with anti-CD38 and 
anti-CD34 antibodies, washed using DMEM, centrifuged 
and resuspended in 100 µl DMEM. ROS were detected by 
DHR-123 reagent (Molecular Probes). For this, DHR-123 
was diluted in DMSO and kept as a 5 mM stock solution 
at  – 20 °C for single use. The aliquots were thawed, diluted 
160 times (30 µM) just before adding 12.5 µl to the HSC 
suspended in 100 µl DMEM to a final concentration of 3 µM. 
The cells were then incubated for 10 min at 37 °C and fol-
lowed by activation with Phorbol 12-myristate 13-acetate 
(PMA) (Sigma-Aldrich. The stock solution of PMA was 
frozen at 1 mg/ml in DMSO, freshly thawed and diluted 
500 times in order to add 12.5 µl to a final concentration 
of 200 ng/ml. After 20 min at 37 °C, the cells were washed 
with PBS, resuspended and analyzed by flow cytometry. 
The red DHR123 turns to green after oxidation.  CD38− and 
 CD34+ positive cells were gated and fluorescence intensity 
of oxidized DHR-123 was measured from the filter channel 
530 nm/30 nm using LSR Fortessa instrument (BD Bio-
sciences) and analyzed by FlowJo software (Tree Star).
Bone marrow transplantations
Human fresh frozen BM  CD34+ cells (LONZA) were thawed 
and stained with APC conjugated mouse anti-Lineage cock-
tail, PE-Cy7-conjugated anti-CD34 and FITC–conjugated 
monoclonal antibodies 1B2, TK8-14, and JG-2 against dif-
ferent epitopes of human VAP-1. For batch cell sorting of 
VAP-1+/lo and VAP-1− cells we used a Sony SH800 cell 
sorter. The NBSGW (immune-deficient, c-Kit-deficient) 
mice not needing irradiation to accept human cells were used 
as BM  recipients. In the VAP-1− group 19,000 cells and 
in the VAP-1− + VAP-1+/lo group 16,250 VAP-1− cells and 
2750 VAP-1+/lo cells were intravenously injected per animal.
For inhibitor studies, human mononuclear umbilical CB 
cells were collected using Ficoll-Plaque gradient centrifuga-
tion (Amersham Pharmacia Biotech, Uppsala, Sweden). Two 
million mononuclear CB cells were intravenously injected 
per animal. One day after the transplantation mice were 
intraperitoneally injected with VAP-1 inhibitor, LJP-1586 
[40] at a dose of 10 mg/kg or with 100 µl of PBS as a con-
trol three times for BM cells and two times for CB cells in a 
week for total of six weeks. At the end of the treatment the 
7856 I. Iftakhar-e-Khuda et al.
1 3
mice were sacrificed and BM were collected. BM cells were 
stained for APC conjugated anti-mouse CD45, BV421 con-
jugated anti-human CD45, APC-Cy7 conjugated anti-mouse 
CD45, PE conjugated anti-human CD45, PE-Cy7-con-
jugated mouse anti-CD34 and APC-conjugated mouse 
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anti-CD38. Samples were run on LSR fortessa and the data 
was analyzed with FlowJo.
Irradiation
A week before irradiation the WT and KO mice were put 
into individually ventilated cages, and provided with acidi-
fied water (pH = 2.8). The mice were given a single dose of 
950 cGy at a rate of 200 cGy/minute.
LJP‑1586 treatment
Cohorts of ten 2-week-old C57BL/6 J mice were intraperito-
neally injected with LJP-1586 at a dose of 10 mg/kg (chosen 
based on the previous publications [40–42]) or with 100 µl 
of PBS as a control for 1 week or 6 weeks.
Statistical analyses
All results are displayed as mean ± SEM. Two-tailed, 
unpaired Student’s t-test was used and p-value < 0.05 was 
used as a threshold for rejecting the null hypothesis. All 
statistical analyses of RNAseq data were performed with 
R 3.6.1. (R Foundation for Statistical Computing, Vienna, 
Austria. URL https:// www.R- proje ct. org/). Model estimates 
were adjusted for the paired experimental design by intro-
ducing a donor effect parameter in the linear model. Let ygij 
be the observed value of gene g corresponding to donor i in 
group j , gi the average effect of individual i in gene g , gj 
the average effect within group j . All employed statistical 
models defined the expected value to be equal to
Heatmaps, multidimensional scaling, gene enrichment 
analysis, and pathway analysis all used log2-counts per 
million (logCPM) values normalized with the voom algo-
rithm from the limma package [43]. Differential expression 
analysis was instead done with package edgeR [44] using its 
quasi-likelihood (QL) pipeline [45]. The linear model is in 
E[ygij] = gi + gj
this case extended by assuming the CPM values to follow 
a Negative Binomial distribution with a variance equal to
Parameter g is the standard deviation associated with 
gene g while  represents the overall biological variability 
across all genes, estimated from the data prior the expres-
sion analysis. Computed p-values were adjusted for multiple 
hypothesis testing with the fdrtool package [46].
Results
VAP‑1 is expressed on HSC in human BM and cord 
blood
AOC3 gene coding for VAP-1 was almost undetectable in 
HSC in database searches [47] (http:// satij alab. org/ cd34/, fig. 
S1a). Since also many prototype HSC protein markers are 
transcribed at a notably low level in HSC, we also stained 
for VAP-1 in bone marrow HSC using flow cytometry. 
Analysis of  Lineage−CD34+CD38− cells, which were also 
 CD90+CD45RA−CD49f+, revealed that a subset of these 
HSC (19.5 ± 2%, n = 5) expressed VAP-1 on the cell surface 
(Fig. 1a, b).
CD34+ cells isolated from human umbilical CB and ana-
lyzed using the same HSC markers also expressed VAP-1 
(Fig. 1c, d). This finding was confirmed using two other 
VAP-1-specific monoclonal antibodies (1B2 and TK8-14) 
which recognize different epitopes of VAP-1 (fig. S1b and 
c). We also confirmed VAP-1 expression in HSC by cyto-
logical stainings of FACS-sorted  CD34+ cells from CB. In 
line with the flow cytometric data, we observed that only few 
cells had high level of VAP-1 protein expression, while the 
rest were VAP-1 negative (Fig. 1e). In conclusion, although 
practically absent at mRNA level, VAP-1 protein is present 
on the cell surface in a small subset of HSC in BM and CB.
VAP‑1+ HSC are undifferentiated HSC
Next we checked, whether there are differences in transcrip-
tomics between BM VAP-1+ and – HSC. RNAseq analyses 
of FACS-sorted human BM VAP-1+ and – HSC populations 
 (Lin−CD34+CD38−CD45RA−  CD90+CD49f+) revealed 
marked differences in their transcriptomics (Fig. 2a and 
Table S2). Among 14,000 expressed genes 1387 genes, 
including cytokines, G-protein coupled receptors, transmem-
brane receptors and kinases (Table S2), had more than five-
fold log change in expression between the VAP-1+ and VAP-
1− HSC populations. Of all differentially expressed genes 
(Fold change > 2, p-value < 0.05), 516 were up-regulated in 








Fig. 1  VAP-1 expression on human BM and CB HSC. a 
Flow cytometric identification of HSC in human BM. The 
plots show the sequential gating strategy for identifying 
 Lineage−CD34+CD38−CD90+CD45RA−CD49f+ HSC (gate P-5). b 
Staining of gate P-5 HSC using the anti-VAP-1 antibody JG-2 or an 
isotype-matched negative control antibody. c Identification of human 
CB HSC from FACS sorted  CD34+ CB cells. d CB HSC (gate P-5) 
analyzed for VAP-1 expression as in  b. e Expression of VAP-1 on 
FACS-sorted  CD34+ CB cells using immunofluorescence staining of 
cytospin slides. The arrow points to a VAP-1+ cell. The inset shows a 
negative control staining. Scale bar 50 µm. In b and d, the numbers 
indicate the percentages of VAP-1+ cells (BM 19.5 ± 2%, n = 5; CB 
51.8 ± 8.7%, n = 10
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and Table S2, 3). Certain unique DEG were further tested 
using real-time qRT-PCR to confirm the differential expres-
sion on VAP-1+ and VAP-1− HSC (Fig. 2d). In line with 
the bulk RNAseq data, TPX2 and CDCA8 were found in 
VAP-1+ cells but were almost undetectable in VAP-1− cells, 
whereas MLLT3 had more than threefold higher expression 
in VAP-1− cells. Gene Set Enrichment Analysis (GSEA) of 
the human HSC associated genes, collected from molecu-
lar signatures database (EPPERT_HSC_R)[48], revealed 
a random distribution of HSC genes in VAP-1+ and VAP-
1− populations (Fig. 2e and Table S4). Analyses of other 
data sets (CB HSC signature,  CD49f+ HSC signature) gave 
comparable results (Fig. S2a–n). These results indicate that 
both VAP-1+ and VAP-1− populations are true HSC with 
distinct transcriptomes.
The top molecular pathway (with more than 50 genes 
involved and false discovery rate (FDR) < 0.02) in VAP-1+ 
population was catalytic activity (Fig. 2f), consistent with the 
ROS-producing enzymatic activity of VAP-1. VAP-1+ and 
 VAP− populations had comparable levels of mRNA of genes 
regulating the production of ROS in general (Fig. S2a–n). 
However, GSEA showed that ROS detoxifying genes such as 
superoxide dismutase 1 and 2 (catalyzing superoxide detoxi-
fication into H2O2) had significant positive correlation to 
VAP-1− population (p = 0.001), suggesting that VAP-1+ 
cells regulate the level of H2O2 involved in HSC mainte-
nance (Fig. 2g and Fig. S2e and Table S4). To check whether 
superoxide dismutase 1 (SOD1) protein was downregulated 
in VAP-1+ cells, we stained and analyzed cord blood cells 
using  Lin−CD34+CD38−CD90+VAP-1+SOD1+. To check 
whether SOD1 protein was downregulated in VAP-1+ cells, 
we stained cord blood cells  (Lin−CD34+CD38−CD90+) for 
VAP-1 and SOD1. We found that SOD1 protein was detected 
mainly in VAP-1 negative cells (p-value < 0.05) (Fig. 
S2o–p). We further analyzed p53, FOXO, p38MAPK, ATM 
and HIF pathways (Fig. 2h and Fig. S2a–n and Table S4), 
which are known to be important for ROS-dependent HSC 
functions. The p53 signaling pathway was highly enriched 
among VAP-1+ cells (Fig. 2i), whereas no statistically sig-
nificant differences were found in p38MAPK, FOXO, ATM 
and HIF signaling pathways (Fig. S2a–n and Table S4). 
Using STITCH data base (http:// stitch. embl. de/) [49] a 
functional association network was drawn using the core 
enriched genes in VAP-1+ population from the p53 path-
way (Fig. 2j). In the top differentially expressed gene list 
many of the cell cycle related genes were enriched in VAP-
1+ cells. Therefore, we used the Meta-analysis workflow in 
Metascape to combine DEGs with cell cycle transition genes 
(G1/S and G2/M) [38] to identify possible correlations. 
From G1/S and G2/M published gene sets encompassing 43 
genes and 55 genes respectively 18% G1/S and 38% G2/M 
genes were enriched among VAP-1+ cells (Fig. S3a). Dur-
ing the hematopoietic stem cell generation three hematopoi-
etic stem progenitor cell (HSPC) clusters HSPC1, HSPC2 
and HSPC3 have been identified [39]. HSPC1 appears first 
and carries highest stemness property, HSPC2 is largely a 
cycling cell population, whereas HSPC3 is closest to lineage 
primed cells. This meta-analysis confirms that VAP-1+ cells 
have similarities with HSPC1 and HSPC2 but have no simi-
larities with HSPC3 (Fig. S3b). Collectively these findings 
indicate that VAP-1+ HSC in BM are a functionally distinct 
subset with a potential to regulate peri-cellular ROS level.
Single cell RNA‑seq profiling of human BM HSC 
reveals two subtypes
Our FACS and RNAseq analyses suggested that VAP-1+ cells 
represent a distinct population of HSC. To resolve the heter-
ogeneity of BM HSC  (Lin−CD34+CD38−CD90+CD45RA−) 
we utilized single cell RNAseq data from Pellin et al. [10] 
(Fig. 3a). After the quality controls we retrieved total of 
1267 high quality HSC for downstream analyses. Unsu-
pervised clustering using Seurat pipeline identified two 
major cell clusters (Fig. 3b) [35]. Since both populations 
expressed previously described markers of HSC and, more 
specifically those of primitive HSC including CD34, CD38 
and MLLT3 [6, 7, 50] (Fig. 3c), we tentatively named them 
as HSC1 (93% of cells) and HSC2 (7% of cells). In fur-
ther sub-clustering with higher resolution, all 89 cells of 
HSC2 were randomly distributed in two dimensional graphs 
(Fig. 3d). Neither HSC1 or HSC2 expressed endothelial, 
human hemogenic endothelial [39] nor stromal or mature 
Fig. 2  VAP-1− and VAP-1+ HSC from adult human BM are tran-
scriptionally different. a Population-distance analysis of VAP-1− and 
VAP-1+ HSC  (Lin−CD34 +  CD38−  CD45RA−  CD90+CD49f+ cells) 
presented as a multidimensional scaling plot of the bulk RNAseq data 
in two dimensions. Each point represents a single biological replicate. 
b A heatmap of genes differentially expressed in VAP-1− and VAP-1+ 
HSC. Colors represent the relative expression of a given gene in com-
parison with the median of all samples. The heat map color scheme 
with the corresponding log2-values is given, n = 4 in both groups. c A 
volcano plot showing the distribution of gene expression changes in 
VAP-1− and VAP-1+ HSC. Genes were plotted as − log10(p-value) on 
the y axis against the log2(fold-change) on the x axis. d Quantitative 
real-time polymerase chain reaction (qPCR) of selected differentially 
expressed genes in VAP-1+ and VAP-1−HSC. The expression inten-
sity was normalized with the expression level of β2 microglobulin 
(B2M). Two samples independent from those used in RNAseq were 
analyzed (p-value < 0.05). e Gene set enrichment analysis (GSEA) 
of the HSC signature genes in VAP-1− and VAP-1+ HSC. Normal-
ized enrichment score (NES). f Gene ontology (GO) molecular sign-
aling pathway analysis for DEGs. Shown are the top five pathways 
(FDR < 0.02 and > 50 observed genes. g GSEA for ROS production, 
hallmark, metabolism and detoxification. NES and FDR-q values are 
shown. h GSEA for p53, MAPK, p38, FOXO, HIF, AKT and ATM 
signaling pathways. NES and FDR-q values are shown. i The enrich-
ment plot of the p53 signaling pathway. j A protein–protein interac-
tion (gray lines, the thickness of which represents confidence and 
strength of the association) network of the enriched genes of the p53 
signaling pathway in VAP-1+ HSC. Proteins are shown as spheres
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blood cell markers (Fig. S4a–c). Similarly, both HSC clus-
ters were negative for leukocyte lineage markers, CD7 and 
CD19 (Fig. S4d) and apoptosis-related genes BCL2, BCL21 
and CASP3 (Fig. S4e). Notably, both HSC1 and HSC2 were 
also practically negative for AOC3 mRNA (Fig. S4f).
When comparing the two HSC clusters, common cell pro-
liferation markers (PCNA, MKI67, MCM2) were character-
istically highly expressed in HSC2, but not in HSC1 cells 
(Fig. 3e). Single cell trajectory analyses of HSC differentia-
tion identified HSC2 as a distinct cluster, and pseudotime 
trajectory analysis suggested that HSC2 evolved later than 
HSC1 (Fig. 3f, g). Trajectories for HSC1 and HSC2 popula-
tions were confirmed using a different algorithm, monocle 
(http:// cole- trapn ell- lab. github. io/ monoc le- relea se/). These 
data suggest that HSC2 has features of proliferating cells on 
their way from dormancy towards expansion.
It is well established that many protein markers of human 
HSC (surface proteins, signaling molecules, transcription 
factors) are expressed at low or undetectable level in mRNA-
based analyses. To validate the identification of the HSC1 
and HSC2 clusters, we further analyzed expression of SPI1, 
a transcription factor important for determining the lifetime 
of HSC [51]. A total of 22 SPI1 cells were identified and 
they distributed sporadically among HSC1 and HSC2 in the 
two dimensional plot (Fig. S5a, b). Prototype HSC cell sur-
face markers (CD90, CD49f, CD33, PROM1, PTPRC) and 
HSC related transcription factors (GATA1, GATA3, HOXB5) 
[6, 7, 11, 51, 52] were expressed at similar, and usually very 
low, levels in HSC1, HSC2 and SPI1 populations (Fig. S5c, 
d). Using the putative HSC2 markers PCNA, MCM2 and 
MKI67 identified above, we verified that HSC2 cluster is dis-
tinct from HSC1 and SPI1 clusters. (Fig. S5e). Collectively, 
these scRNAseq analyses support the concept that HSC2 is 
a unique HSC cluster.
VAP‑1+ HSC are the more differentiated subset 
within HSC
To find out, whether VAP-1 expression discrimi-
nates HSC1 and HSC2 populations we sor ted 
VAP-1+ and VAP-1− cells from human BM HSC 
 (Lin−CD34+CD38−  CD45RA−  CD90+). Using direct 
qPCR from a single cell equivalent of cDNA we tested the 
expression of TYMS and PCNA (representative top DEGs 
for HSC2, see Fig. 3h). TYMS expression was tenfold higher 
(n = 5, p < 0.01) and PCNA expression 3.5 fold higher (n = 5, 
p < 0.03) in VAP-1+ than in VAP-1− cells (Fig. 3i, j). More-
over, the bulk RNAseq VAP-1+ HSC markers TPX2 and 
CDCA8 (Fig. 2c), which were confirmed to be undetectable 
in VAP-1− cells in qPCR analyses (Fig. 2d), were highly 
expressed in HSC2, but were practically absent in HSC1 
when analyzed from the HSC scRNAseq data (Fig. 3k). 
In addition, major genes of p53 pathway were abundantly 
expressed in HSC2 (Fig. 3l), in line with the observation 
that p53 was the most significantly enriched pathway in 
VAP-1+ HSC in bulk RNAseq analyses (Fig. 2i). To confirm 
similarities of VAP-1+ and HSC2 populations, differentially 
expressed genes from bulk and scRNAseq were analyzed for 
Gene Ontology and pathways. Both cell populations syn-
chronously presented multiple pathways involved in entry 
to cell cycle and proliferation (Fig. S6a, b). Collectively, 
scRNAseq data suggest that VAP-1+ HSC correspond to 
 PCNAhigh differentiated HSC2 subset, while VAP-1− HSC 
represent the predominant HSC1 population. Thus, VAP-1 
protein expression may serve as a new HSC2 subset specific 
surface marker.
To validate our in silico analyses, we performed scR-
NAseq of adult human BM VAP-1+ and − HSC. ScRNAseq 
of FACS-sorted human BM VAP-1+ and – HSC populations 
(Lin-CD34 +) revealed that proliferating HSC are mainly 
VAP-1+ HSC. Unsupervised clustering using Seurat pipe-
line identified six major cell clusters (Fig. S7a). VAP-1+ 
HSC contained higher proportions of Cluster 2 and Cluster 
3 and lower proportions of Cluster 0 (Fig. S7b). All four 
samples together pointed out that VAP-1+ cells are substan-
tially distinctly positioned from the VAP-1− cells (Fig. S7c). 
Applying nebulosa to p53 pathway (Fig. S7d), bulk RNAseq 
VAP-1+ HSC markers (Fig. S7e), and HSC2 cell prolifera-
tion markers from Pellin’s data (Fig. S7f), we observed a 
clear expression signal in VAP-1+ clusters. Cell cycle gene 
scoring further confirmed that S.Score and G2M.Score are 
highly enriched among VAP-1+ cells (Fig. S7g). Monocle 
pseudo-time trajectory analysis confirmed that VAP-1+ 
evolved later than VAP-1− cells (Fig. S7h and i).
Fig. 3  Identification of a new subclass of human BM HSC. a A 
schematic presentation of the protocol used for HSC sub-cluster 
identification. b Visualization of two major classes of HSC (HSC1 
and HSC2). Each dot is a single cell colored by cluster assignment. 
c Expression of known HSC markers in HSC1 and HSC2. d Sub-
clustering analysis of the HSC2 subset. e Expression of the indicated 
cell proliferation signature genes in HSC1 and HSC2. Horizontal bars 
indicate the median gene expression. f Single cell trajectory analysis 
of the differentiation path within HSC. Cells are colored according to 
the cluster. g Pseudotime trajectory analyses of HSC differentiation. 
The pseudotime indicator is shown at the top. h A heatmap showing 
the scaled expression of top differentially expressed genes (DEGs) in 
HSC1 and HSC2 clusters. The color scheme is based on z-score dis-
tribution from low (purple) to high (yellow). The left side lists the 
genes specific for the respective HSC subsets. i The outline of the 
protocol used for identifying proliferating VAP-1+ cells in the human 
BM HSC scRNAseq dataset. j qPCR validation of HSC2 genes (from 
a) in VAP-1+ HSC population (p-value < 0.05). k and l Dot plots 
showing the scaled expression levels of top genes (k) and genes of 
p53 pathways (l) differentially expressed in VAP-1+ HSC (identified 
in bulk RNAseq data, Fig. 2b) in HSC1 and HSC2 cells (based on the 
scRNAseq data). The color intensity reflects the expression level, and 
the circle size reflects the proportion of the cells expressing the given 
gene
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VAP‑1 inhibition enhances expansion of HSC in vitro
To test the function of VAP-1 in human HSC, we per-
formed CFU assays. Initially we sorted single HSC from 
CB and cultured them in vitro in a complete methylcellu-
lose medium for 14 days (Fig. 4a). After re-plating and an 
additional 12–14 d incubation, 79% of plated VAP-1− colo-
nies and 50% of the plated VAP-1+ colonies grew (Fig. 4b). 
VAP-1− HSC also generated substantially higher numbers 
of colonies (mean 121) compared to VAP-1+ cells (mean 
69 colonies) (p < 0.01; Fig. 4c). Microscopically CFU-E, 
CFU-GM or CFU-Mix cells were identified in the progeny 
of both VAP-1+ and VAP-1− cells, and the numbers of all 
three CFU subpopulations were increased in the cultures 
starting with sorted VAP-1− cells, although this increase 
was not statistically significant, when the cell types were 
analyzed separately (Fig. 4d).
When BM-derived  CD34+ cells were cultured in methyl-
cellulose-based medium in the presence of a specific VAP-1 
enzyme inhibitor LJP-1586, the number of CFUs formed was 
33% higher after the first plating than the number of CFUs 
formed in control cultures. To determine whether these colo-
nies contained HSC, we dissociated them into single-cell 
suspensions and re-plated the cells. After repeating this pro-
cedure twice (3rd plateing), the number of CFUs formed by 
LJP-1586-treated cultures was 246% higher than the number 
of CFUs formed by control cultures (p < 0.05; Fig. 4e). We 
also cultured  CD34+ cells sorted from human CB for 21 days 
in StemSpan SFEM medium II containing different concen-
trations of LJP-1586. In control cultures the frequency of 
HSC decreased from 37 to 1% already in 8 days. In con-
trast, the frequency of HSC readily expanded in LJP-1586-
treated cultures for up to 21 days (Fig. 4g). HSC expanded 
more than 31 times in cultures treated with 1 µM LJP -1586 
and grown for 18 days compared to the control cells (not 
containing LJP-1586). Expansion of HSC was less efficient 
in cultures treated with higher or lower concentrations of 
LJP-1586. The degree of HSC expansion was donor-depend-
ent, but was consistent in samples sorted from a single donor 
(Fig. 4f, g). On average, in LJP-1586 treated cultures  CD34+ 
cells expanded 234% when compared to cultures without the 
inhibitor (5.4 vs. 2.3, p = 0.027).
Primitive HSC were further assessed using the addi-
tional markers  CD45RA−CD90+CD49f+ (Fig.  4h). 
More than 12% of HSC in gate P-3 were primitive HSC 
 (CD34+CD38−CD45RA−CD90+CD49f+) and the number 
of these was 11 times higher in LJP-1586-treated compared 
to non-treated cultures (Fig. 4h). Using dihydrorhodamine 
(DHR 123) and flow cytometry we found that ROS were 
reduced by 62% (MFI) when the cells were cultured with the 
LJP-1586 inhibitor compared to the control cells (shown for 
BM derived HSC in Fig. S8). In conclusion, VAP-1 inhibi-
tion in liquid cultures expands HSC  (CD34+CD38−) and 
primitive HSC  (CD34+CD38−CD45RA−CD90+CD49f+) 
compared to the untreated cells suggesting that VAP-1 may 
serve as a check-point inhibitor restricting HSC proliferation.
VAP‑1 inhibitors improve HCS engraftment in vivo
Since VAP-1 inhibitor expands HSC in vitro, we wanted to 
study if VAP-1 is involved in expanding HSC also in vivo. 
It is known that in vitro cultured HSC are not comparable 
with freshly isolated HSC. In vitro cultured HSC remark-
ably change their properties within 5 days [53], whereas 
HSC are maintained in vivo without any visible exhaustion 
[54]. In addition, HSC can divide asymmetrically in vitro 
but not all proteins segregate, and asymmetric segregation 
is clearly defined only until granddaughter cells [55]. Thus, 
long term in vitro cultured HSC cannot be used in in vivo 
transfer studies (and this was confirmed by our initial trial; 
data not shown). Therefore, for an in vivo experimental set-
ting we used freshly isolated human HSC and transplanted 
them to NBSGW mice, which were treated by intraperi-
toneal administration of VAP-1 inhibitor. We first trans-
ferred CB derived mononuclear cells (including HSC) to 
NBSGW mice, which accept human cells without irradia-
tion. We treated the mice with VAP-1 inhibitor LJP1586 
or PBS (control) for 6 weeks as schematically presented 
in Fig. 5a. When analyzing the presence of human HSC 
 (mCD45−hCD45+hCD34+hCD38−) in BM, the frequency 
of  CD34+CD38− cells (gate P-4) increased by 63% (2.29 
vs. 1.4, p = 0.014) and the frequency of  CD34+CD38 +cells 
(gate P-5) also showed a trend of increase (15.31 vs. 12.74, 
trend: p = 0.09) in LJP-1586 treated mice (Fig. 5b, c).
For additional in  vivo engraftment studies, we iso-
lated two BM HSC pools by sorting: one containing only 
VAP-1− HSC and one containing 14,5% VAP-1+ HSC (the 
rest were VAP-1− in this pool, since the low numbers of 
VAP-1+ HSC made it technically impossible to use a pool 
containing only VAP-1+HSC). The cells were adoptively 
Fig. 4  Inhibition of VAP-1 expands BM and CB HSC in in vitro cul-
tures. a The number of colonies arising from single-cell sorted VAP-
1+ and VAP-1− CB. b The number of colonies from (a) re-plated and 
cultured for another 12–14 days. c The number of colonies from (b) 
counted by microscopy (p-value < 0.01). d Characteristics and num-
ber of CFU-E, CFU-GM or CFU-MIX colonies. a–d; CB collected 
from 60 donors. e Number of BM HSC in CFU assays in presence 
or absence of VAP-1 inhibition. Five hundred human BM-derived 
 CD34+ cells were cultured under CFU conditions in presence of 
LJP-1586 (0.5  µM) or vehicle. n = two donors, triplicate cultures 
(p-value < 0.05). f Kinetic analyses of sorted  CD38−CD34+ CB-
derived cells cultured with different concentrations of LJP-1586 for 
21  days. Data from one representative donor out of 3 are shown. g 
Effect of LJP-1586 (1 µM) on FACS-sorted  CD38−CD34+ CB cells 
cultured in vitro for 15 d, n = 4 donors (p-value < 0.05). h Analyses of 
CD34 + CD38-CD45RA−CD90+CD49f+ HSC expansion subsequent 
to 15d LJP-1586 treatment measured as fold expansion and CFUs 
(n = 4) (p-value < 0.05)
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Fig. 5  Inhibition of VAP-1 increases the engraftment potential of CB 
and BM HSC in NBSGW mice. a The experimental set up for in vivo 
analysis of mononuclear CB cells with VAP-1 inhibitor. b Gat-
ing strategy of harvested BM cells from recipients at the end of the 
experiment by flow cytometry using antibodies against mouse CD45, 
human CD45, human CD34 and human CD38. c Percentages of cells 
isolated from BM of transplanted mice (n = 7) within the different 
gates defined in (b) (p-value < 0.05). d The experimental scheme for 
in  vivo analyses of VAP-1 – and VAP-1+/lo HSC in the presence of 
VAP-1 inhibitor. e Batch sorting and the frequencies of VAP-1− and 
VAP-1+/lo HSC from human BM in the  CD34+ gate. f In vivo engraft-
ment of VAP-1− and VAP-1+/lo human BM cells in non-irradiated 
NBSGW mice after 42  days. Representative flow cytometric plots 
(percentages of engrafted cells) and quantification from each group 
(n = 3 for each group). The cut-off value for engraftment was set as 
0.1
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transferred to NBSGW mice (Fig. 5d, e). After the trans-
fer, the mice were treated with VAP-1 inhibitor LJP-1586 
for 6 wks or left untreated. None of mice transplanted with 
VAP-1− HSC demonstrated engraftment. In contrast, 3/3 
mice having VAP-1+ cells in the transfer pool and receiv-
ing the VAP-1 inhibitor accepted the human BM engraft-
ment (Fig. 5f). These data collectively suggest that while 
VAP-1+ HSC identifies the proliferating HSC pool, inhi-
bition of VAP-1 activity allows higher than physiological 
rate of HSC engraftment and expansion. This supports the 
idea that VAP-1 is a check-point inhibitor regulating HSC 
proliferation.
The number of HSC and HSPC is increased in the BM 
of VAP‑1‑KO and VAP‑1‑KI mice
Next, we investigated, whether a lack of VAP-1 affects 
the number of HSPC and HSC in the mouse BM. To this 
end, we performed flow cytometric analysis of HSPCs 
and HSCs derived from the BM of VAP-1-KO, VAP-
1-KI (having the VAP-1 protein without enzymatic activ-
ity), and WT mice. The number of HSCs, defined as 
 Lineage−Sca-1+c-Kit+CD150+CD127−CD135− cells, was 
significantly higher in the BM of VAP-1-KO and VAP-
1-KI mice than in the BM of WT mice (0.013% n = 5, 
0.017% n = 5, and 0.011% n = 5, respectively, gate P-6 in 
Fig. 6a). Sequential staining with HSPC markers showed 
that  Lineage−CD127− cells (gate P-4) and c-Kit+Sca-1+ 
cells (gate P-5) were enriched in VAP-1-KO mice (within 
both gates) and VAP-1-KI mice (within gate 5). However, 
unlike in human, mouse HSC were negative for VAP-1 
(Fig. S9a). In fact, VAP-1 colocalized with the endothelial 
cell markers, CD31 and MECA-32 (recognizing PLVAP) 
in the vast majority of arterioles and most microvessels 
(Fig. 6b). Moreover,  lineage−CD150+ cells, which include 
HSPC among other cell types [56] were largely located in 
close proximity to, and likely attached to, VAP-1-expressing 
blood vessels (Fig. 6c) suggesting that VAP-1 is part of the 
hematopoietic niche containing HSPC that is destroyed by 
irradiation(fig. S9b).
Colony forming capacity of BM cells is increased 
in VAP‑1 KO mice
We next used VAP-1-KO mice for functional tests by per-
forming short-term CFU assays with BM cells harvested 
from VAP-1-KO mice aged 1, 9, and 18 months. The total 
colony count included progeny from HSC, multipotent pro-
genitors, and lineage-committed progenitors. The number 
of CFUs was much higher using BM cells isolated from 
VAP-1-KO mice than using BM cells isolated from WT 
mice at all ages, but the difference was at highest using cells 
isolated from 18-month-old mice (eightfold, n = 4 in each 
age matched group; Fig. 6d). We also expanded BM-derived 
HSC and multipotent progenitors (HSPC) on a BM-derived 
feeder layer that had been irradiated [57, 58]. CFU assays 
demonstrated that expansion was increased by ~ twofold 
when HSPC derived from VAP-1-KO mice were grown on 
a VAP-1-KO feeder layer in comparison to cultures on WT 
feeders (Fig. 6e). Expansion was reduced when HSC and 
HSPC derived from VAP-1-KO mice (n = 5) were grown 
on a WT feeder layer and when HSC and HSPC derived 
from WT mice (n = 5) were grown on a VAP-1-KO feeder 
layer (pooled from BM of three KO and three WT mice). 
In conclusion, VAP-1 expressed by stromal cells markedly 
affects the proliferation of HSC and HSPC. Based on these 
experiments, we conclude that VAP-1 is important for main-
tenance of HSC and HSPC. The number of HSC and HSPC 
was increased in VAP-1-KO mice, and the findings made in 
VAP-1-KI mice indicate that this effect was due to the lack 
of VAP-1 enzymatic activity.
VAP‑1 inhibitor increases the numbers of HSC
To confirm that proliferation of HSC is increased in 
VAP-1-deficient mice, we injected 2  weeks old WT 
mice with the small molecule LJP-1586, which blocks 
the enzymatic activity of VAP-1. The treatment was 
continued for 6  weeks. HSC in BM were then ana-
lyzed using the same markers as in Fig. 6a (defined as 
 Lineage−Sca-1+c-Kit+CD150+CD127−CD135− cells). 
The percentage of HSC (gate 6 in Fig. 6a) was 34% (PBS, 
n = 10; LJP-1586, n = 10) higher in LJP-1586-treated mice 
than in control mice (Fig. 7a). When we defined HSC as 
 Lineage−Sca-1+c-Kit+CD150+CD48−CD41− cells [59–62], 
the percentage of these cells was increased by 65% in LJP-
1586-treated mice (Fig. 7b). These results demonstrate that 
the number of HSC is increased in mice treated with LJP-
1586, irrespective of which markers are used to define HSC.
We also performed CFU assays to study the effects of 
VAP-1 inhibition on colony formation. Upon culture in 
methylcellulose-based medium, the number of CFUs formed 
by BM cells isolated from mice treated with LJP-1586 
(n = 4) for 1 week and non-treated control (n = 4) mice did 
not significantly differ (Fig. 7c). This indicates that mice 
must be treated with LJP-1586 for a longer duration to elicit 
effects on stem cell expansion. When the duration of treat-
ment was increased to 6 weeks (n = 10 + 10), the number of 
CFUs formed by BM cells isolated from LJP-1586-treated 
mice was 20% higher than the number of CFUs formed by 
BM cells isolated from the control mice (36.7 vs. 30.5 colo-
nies, p = 0.0396; Fig. 7d). By contrast, the number of CFUs 
formed by peripheral blood (PB) cells did not significantly 
differ between LJP-1586-treated and control mice (49.4 vs. 
52.2 colonies, p = 0.8373). Differential counts of the BM 
cell-derived colonies revealed that the number of CFU-GMs 
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was increased by 22% (14.9 vs. 12.2, p = 0.0729) and the 
number of CFU-GEMMs was increased by 79% (4.3 vs. 
2.4, p = 0.0459) in LJP-1586-treated mice. However, only 
the latter reached statistical significance (Fig. 7e). In sum-
mary, inhibition of the enzymatic activity of VAP-1 in mice 
increases the number of HSC, leading to the generation of 
more CFU-GEMMs.
Discussion
Here we show that VAP-1 protein expression defines a novel 
HSC subset in humans. VAP-1+ HSC are genuine undif-
ferentiated HSC which are transcriptionally distinct from 
the other HSC. VAP-1+ HSC closely resemble a novel HSC 
subpopulation, HSC2, which we identified from scRNAseq 
data. We show that HSC2 are proliferating and developmen-
tally more mature than the other HSC. We also demonstrate 
that VAP-1 deficiency and inhibition of VAP-1 via a chemi-
cal inhibitor increases HSC proliferation and engraftment 
in vivo. Collectively these data suggest that VAP-1 is a new 
check-point inhibitor, which is induced on HSC before they 
undergo further differentiation.
mRNA signal of VAP-1 in HSC, including HSC2, was 
very low. This is not unexpected, since many key protein 
markers for HSC including CD90 is expressed at a nota-
bly low mRNA levels in HSC: This may be due to a slow 
turnover of the message [63]. Alternatively, soluble VAP-1 
protein produced by other cells and found in the blood of 
healthy persons may bind to the surface of HSC. In either 
case, our data show that VAP-1 protein on HSC surface 
identifies a unique subpopulation of HSC.
The enzymatic activity of VAP-1 leads to production of 
ROS, which influence the development and self-renewal 
of HSC [64]. Low levels of ROS are required for mainte-
nance of HSC [65], and intermediate levels of ROS drive 
proliferation and differentiation [64, 66], while high levels 
of ROS lead to damage and exhaustion of the stem cell pool 
[22, 23]. As an important but not the sole source of ROS, 
VAP-1 may help to fine-tune the ROS concentration. Other 
enzymes, apart from SSAOs, do not produce large amounts 
of H2O2 in HSC [67]. Our results from RNAseq analyses 
of BM VAP-1+ and  VAP− HSC together with the findings 
that the p53 signaling pathway was highly enriched among 
VAP-1+ cells and VAP-1 inhibitors decreased ROS produc-
tion suggest that VAP-1 created ROS at least partially act via 
the p53 signaling pathway.
When we took advantage of the existing single cell 
sequencing data from human BM HSC [10] and analyzed its 
possible heterogeneity, we could identify two clearly distinct 
populations, which we named HSC1 and HSC2. Further 
analyses showed that the genes highly expressed in VAP-1+ 
HSC, including CDC8A, and TPX2, were present almost 
exclusively in the HSC2 population. Similarly, sorted VAP-
1+ HSC expressed HSC2 signature genes (TYMS, PCNA) at 
significantly higher levels than did VAP-1− HSC. Addition-
ally, comparison of four DEG lists together unambiguously 
showed that VAP-1+ HSC and HSC2 share common GO 
terms and they cluster together. Therefore, our data suggest 
that VAP-1+ HSC and HSC2 are largely overlapping HSC 
populations. Notably, VAP-1 protein expression should 
thus be a useful marker allowing prospective enrichment of 
HSC2 cells for further studies.
The VAP-1+/HSC2 population shows characteristics 
of proliferating cells. On the other hand, we found that 
inhibition of VAP-1 increases proliferation and engraft-
ment of HSC. The inhibitor experiments support a con-
cept that high levels of ROS produced by VAP-1 inhibit 
HSC proliferation, while the low levels of ROS are sup-
portive for HSC production. In this context it should be 
noted that chemical VAP-1 inhibition regimens used lead 
to reduced and fluctuating VAP-1 activity rather than its 
complete abrogation. We suggest that VAP-1 is a new 
check-point inhibitor controlling HSC proliferation. In this 
scenario, VAP-1 will be induced on HSC surface when 
the cells leave dormancy and move towards a proliferative 
state, i.e. when HSC1 differentiate into HSC2. On HSC2 
cells VAP-1 activity then starts to inhibit proliferation, 
possibly to maintain the stem cell nature of the HSC. If 
VAP-1 is inhibited at this stage, the outcome is enhanced, 
Fig. 6  The number of primitive HSC is increased in BM of VAP-
1-deficient mice. a BM cells of WT, VAP-1-KO, and VAP-1-KI 
mice were stained with Lineage cocktail, anti-CD127, anti-c-Kit 
anti-Sca-1, anti-CD135, and anti-CD150 antibodies and analyzed 
by flow cytometry. The plots show the gating strategy for HSCs. 
While gates P-1, P-2, and P-3 (not shown) exclude debris and dou-
blets, gates P-4, P-5, and P-6 show the sequential enrichment of HSC, 
with gate P-6 representing the purest population. The columns show 
the relative frequency of gated cells among total nucleated cells iso-
lated from WT, KO and SSAO-KI mice (n = 5). Student’s t-test was 
applied (*p-value < 0.05, **p-value < 0.01). b Whole-mount immu-
nofluorescence staining of a mouse femur for VAP-1, MECA-32, and 
PECAM-1/CD31. VAP-1 is present in all vessels (representative of 
10 mice). c Immunofluorescence staining of Lineage-CD150 + HSC 
and VAP-1-expressing blood vessels (green). Arrows indicate HSC 
interacting with VAP-1-expressing blood vessels. M indicates a meg-
akaryocyte expressing CD150 and VAP-1 (representative of 5 mice). 
Scale bars represent 50 μm. d HSC among BM cells. The numbers 
of CFUs formed following seeding of 2500 BM cells isolated from 
young (1-month-old, 1  M), adult (9-month-old, 9  M), and very old 
(18-month-old, 18  M) mice are shown (n = 4). Student t-test was 
applied (*p-value < 0.05, **p-value < 0.01). e The LTC-IC poten-
tial of primitive progenitors among BM cells. The frequencies were 
determined by culturing 12′500 BM cells on irradiated BM-derived 
feeder layers for 4 weeks. Four different combinations were used by 
culturing HSCs derived from WT or VAP-1-KO mice on feeder lay-
ers derived from WT or VAP-1-KO mice. The table provides a sum-
mary of the frequency of HSC in culture from 6′225, 12′500, and 
25′000 starting BM cells (feeder layer from 3 mice, BM HSC from 5 
mice). L-cal software was applied
◂
7868 I. Iftakhar-e-Khuda et al.
1 3
supra-physiological proliferation. In this manner, VAP-1 
on HSC would function analogously to immune check-
point inhibitors on T-cells. These molecules, including 
CTLA-4 and PD-1, are induced on activated T-cells and 
serve as intrinsic brakes for T-cell proliferation and dif-
ferentiation during an immune response, and inhibition 
of check-point inhibitors on T-cells with drugs leads to 
enhanced immune reactions [68, 69].
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Unexpectedly, mouse HSC were found to be negative for 
VAP-1. Since the in vivo experiments utilizing VAP-1 KO 
mice and VAP-1 inhibitor treatments unambiguously dem-
onstrated the role of VAP-1 in HSC proliferation (increase 
in HSC and CFU-GEMM numbers), the effect has to come 
from vascular VAP-1 in mice.  Lineage−CD150+ cells largely 
resided close to VAP-1-expressing blood vessels. This is not 
unexpected because the close proximity of HSC to blood 
vessels has already been reported and the significance of 
the vascular niche has become evident [52, 56]. However, 
the localization of VAP-1 may mean it can contribute to 
the HSC niche via direct contact with HSC by altering the 
microenvironment via its enzymatic activity producing 
ROS. The possibility for direct binding of HSC to vascular 
VAP-1 also exists, as the recent single cell sequencing finds 
Siglec-10 message among HSC [10]. Siglec-10, on the other 
hand, has been shown to be a leukocyte ligand for VAP-1 
[70]. BM irradiation dramatically destroys BM sinusoids, 
which provide the niche for about 80% of dividing and non-
dividing HSC [71–73]. We also witnessed the loss of VAP-1 
in BM vasculature subsequent to irradiation preventing to 
study VAP-1 dependent engraftment of transplanted cells 
after irradiation.
In conclusion, we define VAP-1 as a cell surface marker 
for a novel proliferating HSC subpopulation. Mechanisti-
cally VAP-1 serves as a check point-like inhibitor restricting 
the proliferation of HSC in a manner which at least par-
tially involves VAP-1 dependent regulation of ROS levels. 
Notably, VAP-1 is readily targetable with small molecule 
inhibitors. In fact, different VAP-1 inhibitors have been and 
currently are in clinical trials for inflammatory diseases and 
have not caused any safety concerns (http:// www. pharm axis. 
com. au/ inves tor- centre/ news/ view/ pharm axis- relea ses- succe 
ssful- resul ts- of- phase-1- clini cal- trial- for- boehr inger- ingel 
heim- partn ered- drug- pxs47 28a and https:// www. astel las. 
com/ en/ ir/ ar2017/ pdf/ 2017AR_ 53_ en. pdf). Based on our 
findings, they may be therapeutically exploitable also in 
HSC expansion.
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